✦ LIBER ✦

P-219 T cell depleted (TCD) allogeneic hematopoietic stem cell transplant for older patients with advanced MDS and AML evolved from MDS

✍ Scribed by Tamari, R.; Chung, S.; Devlin, S.; Jakubowski, A.; Papadopoulos, E.; Perales, M.A.; Ponce, D.; Goldberg, J.; Barker, J.; Sauter, C.; Koehne, G.; Young, J.; Giralt, S.; Castro-Malaspina, H.

Book ID: 123214985
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 68 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/S0145-2126(13)70266-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-221 Characteristic of relapse after T

P-221 Characteristic of relapse after T cell depleted (TCD) allogeneic hematopoietic stem cell transplantation in patients with advanced MDS

✍ Tamari, R.; Chung, S.; Devlin, S.; Jakubowski, A.; Papadopoulos, E.; Boulad, F.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Reduced intensity conditioning (RIC) for

Reduced intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HCT) in patients with AML evolved from MDS or therapy related AML

✍ M.R. O’Donnell; R. Roberto; A.S. Stein; J. Palmer; M. Slovak; R. Nakamura; D.S. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Favorable Outcomes in Elderly and High-R

Favorable Outcomes in Elderly and High-Risk Patients with AML and MDS Following T-Cell Depleted Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation

✍ E. Nicholson; S. Mackinnon; K.J. Thomson; J. Sudak; A.K. Fielding; P. Kottaridis 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase II Trial of Reduced Intensity Busu

Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

✍ Chen, Yi-Bin; Li, Shuli; Del Rio, Candice; Coughlin, Erin; Ballen, Karen K.; Cut 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Allogeneic Hematopoietic Stem Cell Trans

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen

✍ G. Alatrash; B. Andersson; M. Pelosini; G. Rondon; M. Qazilbash; S. Giralt; L. d 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Survival Advantage for Patients with AML

Survival Advantage for Patients with AML and MDS Given Allogeneic Hematopoietic STEM CELL Transplantation Using Myeloablative Versus Reduced Intensity Conditioning (RIC) MAY Become Apparent 5-10 YEARS after Transplantation

✍ Shimoni, Avichai; Shem-Tov, Noga; Volchek, Yulia; Danylesko, Ivetta; Yerushalmi, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 64 KB